EGFR and glioblastoma: While it has been suggested that co-expression of the oncogene EGFRvIII with the PTEN mutation is associated with response to pharmacological EGFR inhibition in GBM in vitro models [41], at present there is no robust evidence to suggest that this response is transferrable to clinical practice.